News and commentary from the world of neurology and neuroscience
Investigational Lu AG09222 met primary end point in proof-of-concept trial
But not everyone can reliably identify prodrome events, notes expert
At 48 weeks, atogepant showed consistent safety profile and efficacy
Findings may point to novel biomarker
Headache episodes during long space travel more common than previously thought